

Fig.1




Fig.2




Fig.3




Fig.4




Fig.5




Fig.6




Fig.7




Fig.8




Fig.9




Fig. 10




Fig. 11




Fig.12

0-12 weeks (FAS, N=145)					
Administr ation group	N	Baseline	12 weeks	Amount of change at 12 weeks with respect to baseline	Model-adjusted Treatment difference [1]*
Placebo	49	50.22±10.33	51.93±10.65	1.70±3.20	
Low dose	50	52.28±11.59	54.65±12.14	2.37±3.79	0.71±0.71
High dose	46	51.53±9.89	54.80±11.66	3.27±3.78	1.66±0.73
12-24 weeks (FAS, N=145)					
Administr ation group	N	24 weeks	Amount of change at 24 weeks with respect to baseline	Model-adjusted Treatment difference [2]*	
High dose and short term	49	54.12±12.04	3.90±4.94	1.41±1.05	
Low dose and long term	50	56.21±13.14	3.93±4.76	1.50±1.01	
High dose and long term	46	56.66±12.57	5.13±5.29		
24-36 weeks (FAS, N=135)					
Administr ation group	N	36 weeks	Amount of change at 36 weeks with respect to baseline	Model-adjusted Treatment difference [2]*	
High dose and short term	46	54.76±12.43	3.91±5.55	1.24±1.18	
Low dose and long term	45	56.39±13.56	3.66±5.20	1.64±1.16	
High dose and long term	44	56.35±13.24	4.78±6.00		

Fig.13




Fig.14

0-12 weeks (PPS1, N=134)					
Administration group	N	Baseline	12 weeks	Amount of change at 12 weeks with respect to baseline	Model-adjusted Treatment difference [1]*
Placebo	43	47.91±10.70	49.30±11.19	1.40±2.95	
Low dose	48	50.77±11.92	53.63±13.43	2.85±4.04	1.35±0.75
High dose	43	49.07±9.08	51.98±10.83	2.91±3.44	1.59±0.69

12-24 weeks (PPS2, N=124)				
Administration group	N	Baseline	24 weeks	Amount of change at 24 weeks with respect to baseline
High dose and short term	44	48.25±10.64	52.27±12.62	4.02±4.46
Low dose and long term	43	51.72±12.09	56.30±14.96	4.58±5.58
High dose and long term	37	49.89±9.97	55.41±13.30	5.51±5.64

24-36 weeks (PPS3, N=114)				
Administration group	N	Baseline	36 weeks	Amount of change at 36 weeks with respect to baseline
High dose and short term	36	49.31±11.39	53.81±14.60	4.50±5.61
Low dose and long term	40	51.50±11.21	56.43±14.33	4.93±5.54
High dose and long term	38	50.13±9.63	55.66±13.98	5.53±6.79

Fig.15




Fig.16





Fig.17



Improvement

Fig.18

Simulation Scenario (Weight based dosage 4)									
Weight range	Dose	Treatment				Placebo			
		Δ K-VABS-II-ABC at 12 week ^a			Target attainment (%) ^b	Δ K-VABS-II-ABC at 12 week ^a			Target attainment (%) ^b
		5%	50%	95%		5%	50%	95%	
10 ~ 13 kg	2g BID	-0.8	1.67	4.01	40.5	-1.75	0.92	3.34	19.5
14 ~ 20 kg	4g BID	-0.71	2.06	7.65	51.5	-1.06	1.15	3.3	29
21 ~ 34 kg	6g BID	-0.91	2.13	13.05	54	-1.69	1.02	3.74	29
35 ~ 49 kg	10g BID	-0.07	2.77	20.99	65	-1.56	0.98	3.78	29.5
50 kg ~	14g BID	-0.65	3.74	24.81	73	-1.57	0.96	3.65	27

Simulation Scenario (Phase 2 trial dosage)									
Weight range	Dose	Treatment				Placebo			
		Δ K-VABS-II-ABC at 12 week ^a			Target attainment (%) ^b	Δ K-VABS-II-ABC at 12 week ^a			Target attainment (%) ^b
		5%	50%	95%		5%	50%	95%	
10 ~ 14 kg	2g BID	-0.8	1.67	4.01	40.5	-1.75	0.92	3.34	19.5
15 ~ 24 kg	4g BID	-0.7	2.11	7.72	53	-1.06	1.15	3.3	29
25 ~ 37 kg	7g BID	-0.9	2.32	15.4	56	-1.69	1.02	3.74	29
38 ~ 51 kg	10g BID	-0.068	2.76	20.99	65	-1.56	0.98	3.78	29.5
52 kg ~	14g BID	-0.67	3.73	24.76	73	-1.57	0.96	3.65	27

Target attainment: a ratio of pediatric patients in which the amount of score change in the K-VABS-II-ABC at 12 weeks is increased by 2 points or more with respect to 0 week (base line)